Martin Falbisoner / Wikimedia Commons
Why It Matters
Washington state is seeking accountability from one of the nation’s largest pharmacy operators for its alleged role in fueling the opioid epidemic that devastated communities across the state. The lawsuit against Albertsons—which operates more than 200 pharmacies in Washington and owns Safeway and Haggen—centers on whether the company prioritized profit over public safety by dispensing hundreds of millions of opioid pills with insufficient oversight.
The case reflects a broader accountability movement targeting corporations and institutions blamed for enabling addiction and death across the country.
What Happened
Trial began Monday in King County Superior Court, with Judge Janet Helson presiding. Washington Attorney General Nick Brown’s office alleges that Albertsons dispensed 641 million opioid pills between 2006 and 2022 despite clear warning signs of drug diversion and misuse.
The state argues the company failed to maintain basic due diligence standards, filling approximately 6.5 million prescriptions flagged with red flags that should have triggered investigation. Instead, prosecutors contend, pharmacists lacked the tools and policies needed to catch suspicious orders.
Albertsons has mounted a different defense: the company argues that doctors’ increasing prescriptions—not pharmacy practices—drove the volume of opioids dispensed. An attorney for the company said during opening statements that “without a doctor’s prescription, the gate does not open. So when doctors wrote more prescriptions, pharmacies like ours received more prescriptions to be filled.”
By the Numbers
The scope of alleged dispensing is substantial. A single customer at an Albertsons pharmacy in Kent received over 5,000 opioid pills in a single month. At another location, a family medicine doctor was responsible for 60 percent of all oxycodone dispensed at that store. The state also documented cases where Albertsons knowingly filled prescriptions for patients known to be selling their medications on the street.
The period under scrutiny spans 16 years, from 2006 to 2022. Prior to this trial, Albertsons had already paid $3 million to settle a related case stemming from a 2017 incident at a Safeway location in North Bend, where auditors discovered tens of thousands of missing hydrocodone tablets that were not reported to the Drug Enforcement Administration until months after the discovery.
Company’s Prior History
The North Bend case preceded this broader lawsuit. After that incident, Albertsons created an internal compliance team aimed at preventing future diversion. However, the state alleges the company still failed to report suspicious pharmacy-to-pharmacy orders to the DEA, a requirement intended to flag potential illegal drug trafficking networks.
An attorney for the Attorney General’s office framed the core issue: “Pharmacies are supposed to be the last line of defense against potent addictive medication being misused or diverted into the illegal drug market. This corporation, however, left its pharmacists and other employees without the vital tools needed to fulfill their role.”
What’s Next
The trial is expected to examine internal company communications, pharmacy policies, and expert testimony on how the opioid crisis unfolded in Washington communities. The outcome could set a precedent for holding large retail pharmacy chains accountable for their dispensing practices and may influence similar litigation pending elsewhere in the country.
The case also underscores ongoing accountability efforts by state law enforcement agencies to address the opioid epidemic’s roots, an issue that continues to claim lives across Washington and the broader Pacific Northwest region.
About the Author
